We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Terns Pharmaceuticals Inc (TERN) USD0.0001

Sell:$8.48 Buy:$8.49 Change: $0.21 (2.36%)
Market closed |  Prices as at close on 19 July 2024 | Switch to live prices |
Change: $0.21 (2.36%)
Market closed |  Prices as at close on 19 July 2024 | Switch to live prices |
Change: $0.21 (2.36%)
Market closed |  Prices as at close on 19 July 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its pipeline includes three clinical-stage development programs: TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity and other metabolic diseases. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic stability and liver distribution. It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.

Contact details

1065 East Hillsdale Blvd.
Suite 100, Suite 100
United States
+1 (650) 5255535

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$623.49 million
Shares in issue:
64.68 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Amy Burroughs
    Chief Executive Officer, Director
  • Mark Vignola
    Chief Financial Officer, Treasurer
  • Bryan Yoon
    Chief Operating Officer, General Counsel, Secretary
  • Scott Harris
    Chief Development Officer
  • Sun Jung
    Chief Business Officer
  • Emil Kuriakose
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.